A prebiotic, short-chain fructo-oligosaccharides promotes peak bone mass and maintains bone mass in ovariectomized rats by an osteogenic mechanism
| Autor: | Subhashis Pal, Pragati Singh, Priya Singh, Ashim Mullick, Jiaur R. Gayen, Naibedya Chattopadhyay, Gurudayal Prajapati, Konica Porwal, Shivani Sharma, Chirag Kulkarni, Ravi Sankar Ampapathi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Peak bone mass medicine.medical_specialty Anabolism Ovariectomy Oligosaccharides RM1-950 Butyrate Bone and Bones Rats Sprague-Dawley 03 medical and health sciences Postmenopausal osteoporosis 0302 clinical medicine Osteogenesis Internal medicine Osteoanabolic medicine Animals Humans Osteoporosis Postmenopausal Pharmacology Calcium metabolism Chemistry Catabolism Fructooligosaccharide General Medicine Bone surface referent markers Calcium absorption Urinary calcium Bone biochemical markers Gastrointestinal Microbiome Butyrates Disease Models Animal 030104 developmental biology Endocrinology Prebiotics 030220 oncology & carcinogenesis Ovariectomized rat Female Therapeutics. Pharmacology Bone Remodeling Biomarkers |
| Zdroj: | Biomedicine & Pharmacotherapy, Vol 129, Iss, Pp 110448-(2020) |
| ISSN: | 1950-6007 |
| Popis: | In preclinical studies, fructooligosaccharide (FOS) showed beneficial skeletal effects but its effect on peak bone mass (PBM) and bone loss caused by estrogen (E2) deficiency has not been studied, and we set out to study these effects in rats. Short-chain (sc)-FOS had no effect on body weight, body composition, and energy metabolism of ovary intact (sham) and ovariectomized (OVX) rats. scFOS did not affect serum and urinary calcium and phosphorus levels, and on calcium absorption, although an increasing trend was noted in the sham group. Sham and OVX rats given scFOS had better skeletal parameters than their respective controls. scFOS treatment resulted in a higher bone anabolic response but had no effect on the catabolic parameters. scFOS increased serum levels of a short-chain fatty acid, butyrate which is known to have osteogenic effect. Our study for the first time demonstrates that in rats scFOS at the human equivalent dose enhances PBM and protects against E2 deficiency-induced bone loss by selective enhancement of new bone formation, and implicates butyrate in this process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect